Bausch Health Companies Inc. (BHC) exhibits 45.0% gross margins and 7.6% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 10.5x enterprise multiple and 4.8% implied options volatility.
Sustained 45.0% gross profitability converts into 17.7% operating margin and 7.6% ROIC, outpacing sector cost of capital.
ROIC: 7.6% // GM: 45.0%YoY revenue trajectory of +6.7% paired with 22.00% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +6.7% // FCF YLD: 22.00%Altman Z-Score of 0.45 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.
ALTMAN Z: 0.45 // F-SCORE: 9/9Trading at 21.2x trailing P/E (19.7x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 21.2x // EV/EBITDA: 10.5xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $8.02 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 1.5% net margins.
NET MARGIN: 1.5% // D/E: 0.85x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for BHC & activate live FRED threshold breach alerts.